ClinCom
17September2021

National Study Group Interview with Henit Yanai

Uri Kopylov, ClinCom Member

Take your study to the next level with the IBD National Study Group Meeting at the ECCO Congress


Uri Kopylov 
© ECCO

One of the missions of the Clinical Research Committee of ECCO (ClinCom) is to facilitate innovative clinical research in the area of Inflammatory Bowel Diseases (IBD).

To promote international scientific collaboration among researchers from different European countries, ClinCom established the IBD National Study Group Meeting, which takes place at the annual ECCO Congress. With this great platform, ClinCom enables investigators to have their studies challenged and promoted at the same time. Before the meeting, investigators are invited to provide a study synopsis for their project, including background, design, objectives, outcome parameters, major inclusion and exclusion criteria, statistics and co-variates. Submitted projects are then reviewed by ClinCom and, if found feasible, discussed during the IBD National Study Group Meeting at the ECCO Congress.

Posted in ECCO News, Committee News, Congress News, ClinCom, ECCO'22, Volume 16, Issue 3

17September2021

Report from IIS Award Winner 2021: Nicolas Pierre

Nicolas Pierre, ECCO Member


Nicolas Pierre
© Nicolas Pierre

Blood proteins related to immunoregulation or cellular junctions reveal distinct biological profiles associated with the risk of short-term versus mid/long-term relapse in Crohn’s Disease patients stopping infliximab

In Crohn’s Disease (CD), anti-tumour necrosis factor α (TNFα) therapy can induce mucosal healing and stable remission. When this objective is achieved, treatment de-escalation may be considered for safety, economic and patient preference purposes. Indeed, chronic exposure to anti-TNFα has been linked to serious complications (e.g. lymphoma, infections, melanoma and non-melanoma skin cancers) [1–4], and this treatment is a burden for the healthcare system [5]. On the other hand, around 50% of CD patients relapse 1–2 years after stopping anti-TNFα [6]. Thus, this strategy cannot be proposed to every patient in remission; rather, decisions should be made on an individualised basis [6].

Posted in ECCO News, Committee News, ClinCom, Volume 16, Issue 3, ECCO'21

17September2021

Report on the 5th Advanced ECCO: EduCational COurse for Industry

Shaji Sebastian, ClinCom Member


Shaji Sebastian
© ECCO

The 5th Advanced ECCO: EduCational COurse for Industry, organised by the Clinical Research Committee of ECCO (ClinCom), was one of the highlights of the educational programme during the ECCO’21 Congress and was held virtually, with live presentations and discussions. The course was aimed at our industry partners and had the broad goal of discussing the areas of IBD research of key importance in the immediate future. 

Posted in ECCO News, Committee News, Congress News, ClinCom, Volume 16, Issue 3, ECCO'21

17September2021

Report on the 4th School for Clinical Trialists at ECCO'21

Laurent Beaugerie, ClinCom Member

Laurent Beaugerie
© ECCO

This year’s 4th School for Clinical Trialists, organised by the ECCO Clinical Research Committee (ClinCom), offered an excellent opportunity to review all the key points of the balance between expected efficacy and potential risks of IBD drugs, in the contexts of both clinical trials and routine care.

Posted in ECCO News, Committee News, ClinCom, Volume 16, Issue 3, ECCO'21

29April2021

Y-ECCO/ClinCom call for Y-ECCO Small Research Survey Proposals

The call for research proposals returns with opportunities for Y-ECCO Members to propose and perform a brief, focused research project with ClinCom/Y-ECCO guidance and ECCO support.

Based on the successes of the surveys jointly conducted by the Young ECCO Committee (Y-ECCO) and the Clinical Research Committee of ECCO (ClinCom) at the ECCO Congresses in the past, we are asking Y-ECCO Members to propose a new survey study.

Posted in ECCO News, ClinCom, ECCO'21, Volume 16, Issue 2, Y-ECCO

25March2021

4th School for Clinical Trialists @ ECCO'21

Peter Bossuyt, ClinCom Member


Peter Bossuyt
© ECCO

During the upcoming ECCO Virtual Congress, ClinCom is organising the 4th School for Clinical Trialists. One of ClinCom’s aims is to increase the quality of clinical trials in IBD and to provide new insights into the fast-moving field of clinical trial development. Randomised clinical trials (RCTs) are still the gold standard for the development and registration of new treatment options. 

Posted in ECCO News, Committee News, ClinCom, Volume 16, Issue 1

15December2020

How should IBD clinical research evolve in the COVID era?

Laurent Beaugerie, ClinCom Member


Laurent Beaugerie
© ECCO

 An interview with Gionata Fiorino

During this period when we are so tormented by the SARS-CoV-2 pandemic, Gionata Fiorino, from Humanitas Research Hospital in Milan, agreed to give us his views on the challenges of adapting IBD clinical research.

Posted in ECCO News, Committee News, ClinCom, Volume 15, Issue 4

30September2020

Y-ECCO/ClinCom call for Y-ECCO Small Research Survey Proposals

At the 15th Congress of ECCO in Vienna, the Young ECCO Committee (Y-ECCO) and the Clinical Research Committee of ECCO (ClinCom) jointly conducted a survey of attendees entitled “Decision-making in IBD dysplasia management”. The results are currently being prepared for publication. This project followed on from other successful surveys which led to submission of abstracts at the ECCO Congress and publication of full manuscripts in scientific journals.

Posted in ECCO News, ClinCom, ECCO'21, Volume 15, Issue 3, Y-ECCO

30September2020

ECCO CONFER Cases Round 7

MASTER ECCO CONFER Cases Logo

Call for proposal of rare cases now open!

ECCO COllaborative Network For Exceptionally Rare Case Reports (CONFER) is an initiative to identify, assemble and report together rare IBD cases of clinical relevance, which are otherwise seldom reported. By joining forces with the many Members and supporters of ECCO, a joint report of all similar rare cases can result in a large case series that will advance our knowledge about these uncommon patients.

Posted in ECCO News, Committee News, ClinCom, Volume 15, Issue 3

30September2020

National Study Group Interview with Uri Kopylov

Shaji Sebastian, ClinCom Member

Take your study to the next level with the IBD National Study Group Meeting at the ECCO Congress


Shaji Sebastian 
© ECCO

One of the missions of the Clinical Research Committee of ECCO (ClinCom) is to facilitate innovative clinical research in the area of Inflammatory Bowel Diseases (IBD).

To promote international scientific collaboration among researchers from different European countries, ClinCom established the IBD National Study Group Meeting, which takes place at the annual ECCO Congress. With this great platform, ClinCom enables investigators to have their studies challenged and promoted at the same time. Before the meeting, investigators are invited to provide a study synopsis for their project, including background, design, objectives, outcome parameters, major inclusion and exclusion criteria, statistics and co-variates. Submitted projects are then reviewed by ClinCom and, if found feasible, discussed during the IBD National Study Group Meeting at the ECCO Congress.

Posted in ECCO News, Committee News, Congress News, ClinCom, ECCO'21, Volume 15, Issue 3

Portal